An endoscopically controlled clinical trial on maintenance Ranitidine treatment of scarred duodenal ulcer was carried out in 78 patients, randomly allocated to either 150 mg Ranitidine at night or low-dose antacid when necessary in a 1-year follow-up study. The maintenance Ranitidine regime prevented ulcer relapse in 23 of 31 cases (74.2%), without any significant adverse reaction. In the control group, the relapse was prevented in 12 of 30 cases (40%); the difference was found to be statistically significant.
Ranitidine in long-term duodenal ulcer treatment: A multicentre trial / Di Mario, F.; Albano, O.; Angelini, Giovanni; Cavallini, G.; Doronzo, Francesca; Farini, R.; Francavilla, A.; Naccarato, R.; Scuro, L. A.; Vianello, F.. - In: DIGESTION. - ISSN 0012-2823. - 24:4(1982), pp. 260-263. [10.1159/000198806]
Ranitidine in long-term duodenal ulcer treatment: A multicentre trial
Di Mario, F.;ANGELINI, GIOVANNI;DORONZO, FRANCESCA;
1982-01-01
Abstract
An endoscopically controlled clinical trial on maintenance Ranitidine treatment of scarred duodenal ulcer was carried out in 78 patients, randomly allocated to either 150 mg Ranitidine at night or low-dose antacid when necessary in a 1-year follow-up study. The maintenance Ranitidine regime prevented ulcer relapse in 23 of 31 cases (74.2%), without any significant adverse reaction. In the control group, the relapse was prevented in 12 of 30 cases (40%); the difference was found to be statistically significant.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
